102 related articles for article (PubMed ID: 24756027)
1. Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
Kaur R; Gautam V; Singhal L; Ray P
J Antibiot (Tokyo); 2014 Aug; 67(8):603-4. PubMed ID: 24756027
[No Abstract] [Full Text] [Related]
2. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Prakash SK; Arora V; Prashad R; Sharma VK
J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
[TBL] [Abstract][Full Text] [Related]
3. Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride.
Castanheira M; Duncan LR; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):305-309. PubMed ID: 28969934
[TBL] [Abstract][Full Text] [Related]
4. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
Melchers MJ; van Mil AC; Lagarde C; den Hartigh J; Mouton JW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630197
[TBL] [Abstract][Full Text] [Related]
6. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
8. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Ge Y
J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
10. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
11. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
12. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Sader HS; Hsiung A; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
Pal RB; Pal P; Venkatesh V; Kulkarni KP
J Indian Med Assoc; 2008 Sep; 106(9):605-6, 611. PubMed ID: 19552092
[TBL] [Abstract][Full Text] [Related]
14. In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Maioli E; Debbia EA; Gualco L; Marchese A
New Microbiol; 2008 Jan; 31(1):37-46. PubMed ID: 18437840
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Gonzalez MD; Wallace MA; Hink T; Dubberke ER; Burnham CA
Antimicrob Agents Chemother; 2015 Nov; 59(11):7084-5. PubMed ID: 26282409
[TBL] [Abstract][Full Text] [Related]
16. High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins.
Goyanes MJ; Cercenado E; Insa R; Morente A; Alcalá L; Bouza E
Rev Esp Quimioter; 2007 Jun; 20(2):216-21. PubMed ID: 17893759
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of antimicrobial resistance in an oncology center in eastern India.
Bhattacharya S; Goel G; Mukherjee S; Bhaumik J; Chandy M
Infect Control Hosp Epidemiol; 2015 Jul; 36(7):864-6. PubMed ID: 25899762
[No Abstract] [Full Text] [Related]
18. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
19. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
20. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
